Form 4: Singular Genomics Systems COO Reports Stock Transactions

Jyotsna Ghai, Chief Operating Officer of Singular Genomics Systems, reports the acquisition of 1,666 shares of common stock upon the vesting of Restricted Stock Units.

Summary

• On October 2, 2024, Jyotsna Ghai, the Chief Operating Officer of Singular Genomics Systems, acquired 1,666 shares of common stock.
• This acquisition resulted from the vesting of Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of the company's common stock.
• 25% of the RSUs vested on October 2, 2024, with the remaining RSUs vesting in 12 equal quarterly installments starting January 2, 2025.
• The reported securities amounts have been adjusted to reflect a 1-for-30 reverse stock split that occurred on June 26, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock transactions by a company officer, indicating a neutral sentiment.

Positives

• The vesting of RSUs indicates a continued alignment of the COO's interests with those of the shareholders.

Future Outlook

The remaining RSUs will continue to vest in equal quarterly installments, beginning on January 2, 2025.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.

Key Dates